Monopar Therapeutics Inc. — Q1 2021 Form 10-Q
Reporting period: Three months ended March 31, 2021. Monopar is a clinical-stage biopharmaceutical company with no approved products and no operating revenue. Its pipeline includes Validive, camsirubicin, and preclinical MNPR-101 and related compounds.
Financial and operating highlights
| Metric | Q1 2021 | Prior comparable period / change |
|---|---|---|
| Revenue | $0 | No product revenue in either period |
| R&D expense | $1.207 million | $0.344 million; up $0.863 million |
| General and administrative expense | $0.688 million | $0.792 million; down $0.104 million |
| Total operating expenses | $1.895 million | $1.136 million; up $0.759 million |
| Net loss | $1.884 million | $1.091 million; loss increased $0.793 million |
| Cash used in operations | $1.938 million | $1.126 million used |
| Cash and cash equivalents | $25.723 million | $16.737 million at December 31, 2020 |
| Total liabilities | $0.806 million | $1.177 million at December 31, 2020 |
There was no debt reported. Operating or gross margins are not meaningful because the company had no revenue. Net loss per share was $0.16, versus $0.10 in Q1 2020. Stockholders’ equity was $25.100 million at March 31, 2021.
Material changes and liquidity
- R&D expense rose primarily due to camsirubicin trial planning and manufacturing, higher and additional R&D personnel costs, and Validive trial and manufacturing costs.
- Net cash provided by financing was $10.921 million, principally from $10.925 million in net proceeds under the JonesTrading at-the-market sales agreement. The company sold 1,104,047 shares under the agreement during the quarter; shares outstanding increased to 12,569,933 from 11,453,465 at year-end.
- Cash increased by $8.986 million during the quarter after operating cash use and financing proceeds. Management estimated available cash would fund planned operations at least through June 2022, based on cash available as of April 30, 2021. Management reported no substantial doubt about going concern through that period.
Outlook, commentary, and risks
- Validive: The Phase 2b/3 VOICE trial had begun dosing, with the first patient dosed announced in February 2021. Management anticipated interim Phase 2b completion in the first half of 2022 and Phase 3 enrollment completion in Q1 2023. Completing the program, including a possible smaller confirmatory Phase 3 trial, will require additional funding in the millions or tens of millions of dollars, or a suitable partner; the amount depends on collaboration arrangements.
- Camsirubicin: The company was assessing alternatives after being unable to obtain regulatory approval to initiate the planned Phase 2 trial in Spain. It expected to start a dose-escalation run-in trial in the U.S. or another country in the second half of 2021 and said current funds were sufficient to obtain topline results from that run-in, but further development will need additional funding. The planned GEIS-led Phase 2 study is expected to require company support averaging approximately $2 million to $3 million annually.
- MNPR-101 and COVID-19 collaboration: Development included preclinical work on uPAR-targeted radio-immunotherapeutics with NorthStar and collaborators. Expenses through April 30, 2021 were described as immaterial; efficacy and development remain uncertain.
- The company expects continuing losses and rising development costs and anticipates pursuing equity or debt financing, collaborations, or grants. If financing or a partner is unavailable, it may need to delay, reduce, out-license, or terminate programs. Equity financing would dilute existing holders.
- Key risks include clinical-trial results, enrollment and regulatory timing, third-party manufacturing and trial execution, intellectual-property protection, competition, financing availability, and COVID-19 effects. No material changes to the risk factors in the 2020 Form 10-K were reported. No material legal claims were reported.
Important facts for investors to verify
- Whether the company secures financing or a Validive partner sufficient to complete the VOICE program, including any confirmatory trial.
- Actual VOICE enrollment and interim Phase 2b timing compared with management’s projections.
- Whether camsirubicin’s run-in trial starts as planned outside Spain and whether later-stage development funding is secured.
- Cash burn, future equity issuance and dilution, and whether the stated runway remains achievable as trial spending increases.
- Clinical and regulatory evidence supporting the pipeline; prior Validive and camsirubicin results described in the filing are not guarantees of future success.